Distinguished in Primary Immunodeficiency (PID)

Dr. Donald L. Mcneil

Allergy and Immunology
Ohiohealth Corporation
3595 Olentangy River Rd, 
Columbus, OH 
Accepting New Patients
Distinguished in Primary Immunodeficiency (PID)
Ohiohealth Corporation
3595 Olentangy River Rd, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Donald Mcneil is an Allergy and Immunologist in Columbus, Ohio. Dr. Mcneil is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Allergic Rhinitis, and Sinusitis. Dr. Mcneil is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 3 clinical trials in the study of Primary Immunodeficiency (PID).

Specialties
Allergy and Immunology
Licenses
Allergy & Immunology in OH
Hospital Affiliations
Licking Memorial Hospital
Genesis Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

OHIOHEALTH CORPORATION
3595 Olentangy River Rd, Columbus, OH 43214

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Biological
Study Phase: Phase 4
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 2
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 7 Less Clinical Trials

5 Total Publications

Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
Journal: Journal of clinical immunology
Published: March 08, 2024
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. Roger A. Friedman
Allergy and Immunology
Advanced in Primary Immunodeficiency (PID)
Dr. Roger A. Friedman
Allergy and Immunology

Ohio ENT & Allergy Physicians

3545 Olentangy River Rd, Suite 200, 
Columbus, OH 
 (0.2 miles away)
614-827-0021
Languages Spoken:
English
See accepted insurances

Roger Friedman is an Allergy and Immunologist in Columbus, Ohio. Dr. Friedman is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Allergic Rhinitis, Sinusitis, Grass Allergy, and Common Variable Immune Deficiency.

Advanced in Primary Immunodeficiency (PID)
Dr. Casey D. Curtis
Allergy and Immunology
Advanced in Primary Immunodeficiency (PID)
Dr. Casey D. Curtis
Allergy and Immunology

Osu Otolaryngology Head And Neck Surgery LLC

915 Olentangy River Rd, 
Columbus, OH 
 (3.8 miles away)
614-366-3687
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Casey Curtis is an Allergy and Immunologist in Columbus, Ohio. Dr. Curtis is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Common Variable Immune Deficiency, Vibratory Urticaria, Chronic Spontaneous Urticaria (CSU), and Allergic Rhinitis. Dr. Curtis is currently accepting new patients.

Advanced in Primary Immunodeficiency (PID)
Dr. Samantha R. Gendelman
Allergy and Immunology | Pediatrics
Advanced in Primary Immunodeficiency (PID)
Dr. Samantha R. Gendelman
Allergy and Immunology | Pediatrics

Psf PLLC

8080 Ravines Edge Ct, Suite 100, 
Columbus, OH 
 (6.4 miles away)
800-999-1249
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samantha Gendelman is an Allergy and Immunologist and a Pediatrics provider in Columbus, Ohio. Dr. Gendelman is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Common Variable Immune Deficiency, Allergic Rhinitis, Primary Immunodeficiency (PID), and Sinusitis. Dr. Gendelman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcneil's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile